RxDoctor Payments Data

Samuel Shewan, PA

Physician Assistant · Salt Lake City, UTNPI 1669875886

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (51.1%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Sanofi accounts for 78.0% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $14,486 and has fallen 82.2% since, to $2,582 in 2025. Among physician assistant clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$22,167in general payments, 2019–2025

Across 68 payments — averaging $325.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$17K
  • GSK$2K
  • Janssen Scientific Affairs, LLC$1K
  • Pfizer$635
  • Johnson & Johnson$459
  • Adaptive Biotechnologies Corporation$201
  • plus $546 from 4 others

What the payments were for

  • Consulting fees$2,76812%
  • Speaking & faculty fees$11,33351%
  • Travel & lodging$4,80622%
  • Food & beverage$3,25915%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,167 in reported general payments places this provider in the 95th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$52,994
Medicare patients
200
Services billed
810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban31$37,191
XareltoRivaroxaban18$26,960
Acyclovir135$2,012
ValacyclovirValacyclovir Hcl18$1,568
CholestyramineCholestyramine (With Sugar)13$975
Gabapentin47$935
Esomeprazole Magnesium22$732
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim45$656
Oxycodone Hcl58$592
Pregabalin18$481
Morphine Sulfate ErMorphine Sulfate19$376
Ondansetron OdtOndansetron18$308
Omeprazole24$260
Trazodone Hcl20$247
Ondansetron Hcl22$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$635$37,19131 claims
Johnson & JohnsonXarelto$459$26,96018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →